Category: CovidienSyndicate content

The Street cheers changes to the Medtronic, Covidien deal

October 3, 2014 by Brian Johnson

Traders on Wall Street rewarded the medtech giants after Medtronic announced it was planning to use "external financing" to pay for the Covidien deal.

Medtronic is still in on Covidien buyout

Medtronic is still in on Covidien buyout

October 3, 2014 by Brad Perriello

Medtronic says it will still pursue the acquisition of Covidien, using $16 billion in "external financing" to back the deal instead of the foreign cash it planned to use.

Medtronic is still in on Covidien buyout

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Medtronic, Covidien name peripherals biz transition team

October 1, 2014 by Alex Soule

Medtronic and Covidien appoint representatives to the integration team charged with combining their peripheral vascular businesses as part of their $43 billion merger.

Covidien, Medtronic name peripherals biz transition team

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

New inversion rules are unlikely to scuttle Medtronic's pending $43B merger with Covidien | The week in medtech M&A

October 1, 2014 by MassDevice

Here's a look at some of the top regulatory stories for medical device companies this week: New inversion rules unlikely to scuttle Medtronic's $43B Covidien buy; New U.S. tax rules may lead Medtronic to redo inversion deal; Ackman threatens to sue Allergan again over potential Salix deal; Tengion is on the auction block

New inversion rules unlikely to scuttle Medtronic's $43B Covidien buy

September 24, 2014 by Brad Perriello

New U.S. tax rules may lead Medtronic to redo inversion deal

September 29, 2014 by MassDevice

Medtronic is likely to attempt a renegotiation of its $43 billion acquisition of Covidien now that the U.S. Treasury Dept. has changed the rules on tax inversion deals.

New U.S. tax rules may lead Medtronic to redo inversion deal

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

TriVascular Tech recall of stent grafts may drag down full-year revenues | Medtech Wall Street news for the week of September 22, 2014

September 25, 2014 by MassDevice

Here's a look at some of the top Wall Street stories for medical device companies this week: TriVascular Tech's stent graft recall could hurt the bottom line; Alere unveils $3.82B privatization plan; Medtronic, Covidien slide on new U.S. inversion rules; Baxano puts itself on the auction block; Philips to carve out lighting biz, merger healthcare & consumer units

TriVascular Tech's stent graft recall could hurt the bottom line

September 19, 2014 by Arezu Sarvestani

TriVascular Tech's stent graft recall could hurt the bottom line

New inversion rules unlikely to scuttle Medtronic's $43B Covidien buy

September 24, 2014 by Brad Perriello

New U.S. Treasury rules on inversion deals are unlikely to scuttle Medtronic's pending $43 billion merger with Covidien, analysts say, but are likely to make it more complicated and expensive.

New inversion rules unlikely to scuttle Medtronic's $43B Covidien buy
Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp